Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

The trial contains standard assessments of safety, tolerability and pharmacokinetics. The clinical endpoints reflect change in symptom frequency and severity and the data should be available later in 2008.

GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II trial in patients with major depressive disorder. Enrollment of approximately 150 subjects is anticipated in this 6-week randomized, double-blind, placebo-controlled trial.

In addition to the two compounds listed above, GSK has also successfully completed a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression.

Urocortin 2 for Congestive Heart Failure (CHF) Continues Preclinical Evaluation

Initiation of longer term (up to 72 hours in duration) Phase II clinical trials of urocortin 2 are awaiting additional preclinical data. The Company has identified five preclinical studies necessary to support the longer period of infusion in the clinical program. Two of these five preclinical studies were successfully completed by July 2008. The two completed studies were non- GLP toxicology and safety assessment studies over 14 days of continuous infusion in distinct species models. The favorable results of these studies now await confirmation in the GLP preclinical studies anticipated later in 2008.

Indiplon Update

The Company met with the FDA in July for an end of review meeting related to the December 12, 2007 approvable letter for indiplon capsules. The FDA meeting focused on the three additional requirements outlined in the approvable letter. After exchange of correspondence regarding meeting minutes, the Company is awaiting the FDA's final version of these minutes to determine the next course of action related to indiplon capsules.

Conference Call and Webcast Today at 5:00 p.m. Eastern Daylight Time

Neurocrine will hold a live conference call and webcast tod
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... , August 18, 2014 ... Systems Market, By Application (Municipal Wastewater Treatment and ... Sheet and Multi Tubular), By Configuration (Internal/Submerged and ... published by MarketsandMarkets, The market for membrane bioreactor ... 2019, growing at a CAGR of 15.28% between ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... its Board of Directors.  Mr. Voyticky is currently President ... an oil and gas exploration company, and has more ... merger and acquisition consulting. The Genesis Biopharma Board now ...
... WOODLANDS, Texas, July 18, 2011 One of the ... to achieve Meaningful Use requirements in the coming years. ... learning more about Meaningful Use requirements and how these ... a free webinar at 1 p.m. EDT (10 a.m. ...
... 90% , Reduction in HIV ... SEEK, a privately owned biopharmaceutical company specializing,in ... of its HIV-v vaccine which demonstrates a one,log (approx ... placebo group, after just a single vaccine,injection. Gregory Stoloff, ...
Cached Biology Technology:Genesis Biopharma Names David Voyticky to Board of Directors 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6
(Date:8/19/2014)... , August 19, 2014 Smart ... Digital Wallet Choices as latest developments, ad campaigns and ... (NASDAQ: EBAY ), Amazon.com Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:8/19/2014)... protect their young have bigger brains than counterparts that ... British Columbia study. , Stickleback fish are well known ... male of the species, rather than the female, cares ... females and researchers wanted to find out if the ... caregivers. , In the study, published recently in ...
(Date:8/18/2014)... major Arizona watershed may lose access to important segments ... is reduced by the effects of climate warming, new ... in the Verde River Basin, are already threatened or ... resources throughout the river and its tributary streams. The ... (Gila robusta) and Sonora sucker (Catostomus insignis). , A ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... at Johns Hopkins have discovered how to block a molecular ... oxygen during a stroke. The Hopkins study, conducted on mice, ... protein on the surface of nerve cells called the EP1 ... as ONO-8713, turns it off. , The finding ...
... garden compost to forest greenery, the mold Aspergillus fumigatus ... its impact. The most common mold causing infection, A. ... among people with weakened immune systems. , Now, in ... scientists at The Institute for Genomic Research (TIGR) and their ...
... Chinese men are selectively switching from traditional Chinese ... but sticking with tradition for ailments such as ... published in Environmental Conservation. , The finding supports ... at the advent of Viagra's commercial release in ...
Cached Biology News:Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 2Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 3Breaking the mold: Research teams sequence three fungus genomes 2Viagra's hidden help for wildlife 2
... Features hardwall acrylic panels mounted ... to form a free-standing modular ... Class 10/ISO 3. Optional ceiling ... ionizers are configured to customer ...
...
... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
...
Biology Products: